Mũ thị trường của Intellipharmaceutics International Inc. là gì (IPCIF)

Giới hạn thị trường của Intellipharmaceutics International Inc. (IPCIF) là $4.96M

Intellipharmaceutics International Inc. (IPCIF) Cổ Phiếu Đang Lưu Hành

Q: Giá của Intellipharmaceutics International Inc. là bao nhiêu (IPCIF)

Giá của Intellipharmaceutics International Inc. (IPCIF) là $0.15

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.

Năm	Cổ phiếu lưu hành	Thay đổi
2026 (TTM)	33.09M	0.00%
2022	33.09M	12.45%
2021	29.43M	24.90%
2020	23.56M	9.18%
2019	21.58M	353.15%
2018	4.76M	53.55%
2017	3.10M	16.16%
2016	2.67M	12.34%
2015	2.38M	3.11%
2014	2.31M	17.18%
2013	1.97M	13.98%
2012	1.73M	15.10%
2011	1.50M	37.47%
2010	1.09M	-51.30%
2008	2.24M	13.63%
2007	1.97M	124.16%
2006	879.29K	10.85%
2005	793.22K	15.41%
2004	687.29K	11.69%
2003	615.38K	27.29%
2002	483.46K	7.69%
2001	448.93K	2.77%
2000	436.82K	49.40%
1999	292.38K	0.00%

Năm

Cổ phiếu lưu hành

Thay đổi

2026 (TTM)

33.09M

0.00%

2022

33.09M

12.45%

2021

29.43M

24.90%

2020

23.56M

9.18%

2019

21.58M

353.15%

2018

4.76M

53.55%

2017

3.10M

16.16%

2016

2.67M

12.34%

2015

2.38M

3.11%

2014

2.31M

17.18%

2013

1.97M

13.98%

2012

1.73M

15.10%

2011

1.50M

37.47%

2010

1.09M

-51.30%

2008

2.24M

13.63%

2007

1.97M

124.16%

2006

879.29K

10.85%

2005

793.22K

15.41%

2004

687.29K

11.69%

2003

615.38K

27.29%

2002

483.46K

7.69%

2001

448.93K

2.77%

2000

436.82K

49.40%

1999

292.38K

0.00%

Công ty	Cổ phiếu lưu hành	Chênh lệch	Quốc gia
Novo Nordisk A/S NVO.US	4.45B	13,340.60%	DK
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	667.24%	US
Regeneron Pharmaceuticals, Inc. REGN.US	102.90M	210.95%	US
UCB SA UCB.BR	190.00M	474.14%	BE
Argenx SE ARGX.US	61.42M	85.60%	NL

Công ty

Cổ phiếu lưu hành

Chênh lệch

Quốc gia